Acute Treatment Therapies for Pediatric Migraine: A Qualitative Systematic Review

Headache

Volumn 56, Issue 1, 2016, Pages 49-70

  Patniyot, Irene R ^a,b   Gelfand, Amy A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

acute pediatric migraine; emergency room headache treatment; pediatric headache

Indexed keywords

ALMOTRIPTAN; BUPIVACAINE; CHLORPROMAZINE; DIHYDROERGOTAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; IBUPROFEN; KETOROLAC; MAGNESIUM; OPIATE; PARACETAMOL; PROCHLORPERAZINE; PROPOFOL; RIZATRIPTAN; SUMATRIPTAN; VALPROIC ACID; ZOLMITRIPTAN;

EMERGENCY CARE; EMERGENCY WARD; HUMAN; MIGRAINE; OUTPATIENT DEPARTMENT; PRIMARY HEADACHE; PRIORITY JOURNAL; QUALITATIVE RESEARCH; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; VISUAL ANALOG SCALE; CHILD; HOSPITAL EMERGENCY SERVICE; MIGRAINE DISORDERS; PEDIATRICS; PRESCHOOL CHILD; TREATMENT OUTCOME;

CHILD; CHILD, PRESCHOOL; EMERGENCY SERVICE, HOSPITAL; HUMANS; MIGRAINE DISORDERS; PEDIATRICS; TREATMENT OUTCOME;

EID: 84956718129     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/head.12746     Document Type: Review

References (59)

1. Kedia S, Ginde AA, Grubenhoff JA, Kempe A, Hershey AD, Powers SW., Monthly variation of United States pediatric headache emergency department visits. Cephalalgia. 2014; 34: 473-478.
2. Richer LP, Laycock K, Millar K, et al., Treatment of children with migraine in emergency departments: National practice variation study. Pediatrics. 2010; 126: e150-e155.
3. Legault G, Eisman H, Shevell MI., Treatment of pediatric status migrainosus: Can we prevent the "Bounce Back"? J Child Neurol. 2011; 26: 949-955.
4. Eapen A, Sivaswamy L, Agarwal R, Thomas R., Management of pediatric migraine in a tertiary care versus community based emergency department: An observational pilot study. Pediatr Neurol. 2014; 50: 164-170.
5. Trottier ED, Bailey B, Lucas N, Lortie A., Prochlorperazine in children with migraine: A look at its effectiveness and rate of akathisia. Am J Emerg Med. 2012; 30: 456-463.
6. Blumenthal HJ, Weisz MA, Kelly KM., Patients with primary headache disorders in the emergency department. Headache Quarterly. 2000; 11: 25-31.
7. Richer L, Graham L, Klassen T, Rowe B., Emergency department management of acute migraine in children in Canada: A practice variation study: CME. Headache J Head Face Pain. 2007; 47: 703-710.
8. Nicholson, RA, Seng, EK, Smith, TR, Dummitt, BW, Yount, BW., Pediatric migraine treatment: Poor adherence to evidence-based acute medication guidelines. Headache. 2015; 55: 132-133.
9. Tfelt-Hansen P, Block G, Dahlöf C., Guidelines for controlled trials of drugs in migraine. Cephalalgia. 2000; 20: 765-786.
10. rd edition (beta version). Cephalalgia. 2013; 33: 627-808.
11. Richer L, Craig W, Rowe B., Randomized controlled trial of treatment expectation and intravenous fluid in pediatric migraine. Headache J Head Face Pain. 2014; 54: 1496-1505.
12. Hämäläinen ML, Hoppu K, Valkeila E, Santavuori P., Ibuprofen or acetaminophen for the acute treatment of migraine in children a double-blind, randomized, placebo-controlled, crossover study. Neurology. 1997; 48: 103-107.
13. Lewis DW, Kellstein D, Dahl G, et al., Children's ibuprofen suspension for the acute treatment of pediatric migraine. Headache J Head Face Pain. 2002; 42: 780-786.
14. Bachur RG, Monuteaux MC, Neuman MI., A comparison of acute treatment regimens for migraine in the emergency department. Pediatrics. 2015; 135: 232-238.
15. Kabbouche MA, Vockell A-LB, LeCates SL, Powers SW, Hershey AD., Tolerability and effectiveness of prochlorperazine for intractable migraine in children. Pediatrics. 2001; 107: e62-e62.
16. Trottier ED, Bailey B, Dauphin-Pierre S, Gravel J., Clinical outcomes of children treated with intravenous prochlorperazine for migraine in a pediatric emergency department. J Emerg Med. 2010; 39: 166-173.
17. Brousseau DC, Duffy SJ, Anderson AC, Linakis JG., Treatment of pediatric migraine headaches: A randomized, double-blind trial of prochlorperazine versus ketorolac. Ann Emerg Med. 2004; 43: 256-262.
18. Kanis JM, Timm NL., Chlorpromazine for the treatment of migraine in a pediatric emergency department. Headache J Head Face Pain. 2014; 54: 335-342.
19. Cutrer FM, Limmroth V, Moskowitz MA., Possible mechanisms of valproate in migraine prophylaxis. Cephalalgia. 1997; 17: 93-100.
20. Reiter PD, Nickisch J, Merritt G., Efficacy and tolerability of intravenous valproic acid in acute adolescent migraine. Headache J Head Face Pain. 2005; 45: 899-903.
21. Sheridan D, Sun B, O'Brien P, Hansen M., Intravenous sodium valproate for acute pediatric headache. J Emerg Med. 2015;49: 1-5.
22. Krusz JC, Scott V, Belanger J., Intravenous propofol: Unique effectiveness in treating intractable migraine. Headache. 2000; 40: 224-230.
23. Sheridan DC, Spiro DM, Nguyen T, Koch TK, Meckler GD., Low-dose propofol for the abortive treatment of pediatric migraine in the emergency department. Pediatr Emerg Care. 2012; 28: 1293-1296.
24. Wang F, Van Den Eden SK, Ackerson LM, Salk SE, Reince RH, Elin RJ., Oral magnesium oxide prophylaxis of frequent migrainous headache in children: A randomized, double-blind, placebo-controlled trial. Headache. 2003; 43: 601-610.
25. Gertsch E, Loharuka S, Wolter-Warmerdam K, Tong S, Kempe A, Kedia S., Intravenous magnesium as acute treatment for headaches: A pediatric case series. J Emerg Med. 2014; 46: 308-312.
26. Gelfand AA, Reider AC, Goadsby PJ., Outcomes of greater occipital nerve injections in pediatric patients with chronic primary headache disorders. Pediatr Neurol. 2014; 50: 135-139.
27. Bartsch T, Goadsby PJ., Stimulation of the greater occipital nerves induces increased central excitability of dural afferent input. Brain. 2002; 125 (Pt 7): 1496-1509.
28. Blumenfeld A, Ashkenazi A, Napchan U, et al., Expert consensus recommendations for the performance of peripheral nerve blocks for headaches: A narrative review. Headache 2013; 53: 437-446.
29. Mellick LB, Pleasant MR., Do pediatric headaches respond to bilateral lower cervical paraspinous bupivacaine injections? Pediatr Emerg Care. 2010; 26: 192-196.
30. Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB., Acute migraine medications and evolution from episodic to chronic migraine: A longitudinal population-based study. Headache J Head Face Pain. 2008; 48: 1157-1168.
31. Mazer-Amirshahi M, Dewey K, Mullins PM, et al., Trends in opioid analgesic use for headaches in US emergency departments. Am J Emerg Med. 2014; 32: 1068-1073.
32. D. Lewis, S. Ashwal, A. Hershey, D. Hirtz, M. Yonker, S. Silberstein,. Practice parameter: Pharmacological treatment of migraine headache in children and adolescents. Neurology. 2004; 63: 2215-2224.
33. Nicholson RA, Seng EK, Smith TR, Dummitt, BW, Yount, BW., Opioid prescribing patterns in pediatric migraine, 2009-2014. Headache. 2015; 55: 161-162.
34. Levy D, Jakubowski M, Burstein R., Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT 1B/1D receptor agonists. Proc Natl Acad Sci U S A. 2004; 101: 4274-4279.
35. Brandes JL, Kudrow D, Stark SR, et al., Sumatriptan-naproxen for acute treatment of migraine: A randomized trial. JAMA. 2007; 297: 1443-1454.
36. Drugs @ FDA. FDA Approved Drug Products. Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm (accessed July 29, 2015).
37. Linder SL, Mathew NT, Cady RK, Finlayson G, Ishkanian G, Lewis DW., Efficacy and tolerability of almotriptan in adolescents: A randomized, double-blind, placebo-controlled trial. Headache J Head Face Pain. 2008; 48: 1326-1336.
38. Ahonen K, Hämäläinen ML, Eerola M, Hoppu K., A randomized trial of rizatriptan in migraine attacks in children. Neurology. 2006; 67: 1135-1140.
39. Ho TW, Pearlman E, Lewis D, et al., Efficacy and tolerability of rizatriptan in pediatric migraineurs: Results from a randomized, double-blind, placebo-controlled trial using a novel adaptive enrichment design. Cephalalgia. 2012; 32: 750-765.
40. Rothner AD, Wasiewski W, Winner P, Lewis D, Stankowski J., Zolmitriptan oral tablet in migraine treatment: High placebo responses in adolescents. Headache J Head Face Pain. 2006; 46: 101-109.
41. Evers S, Rahmann A, Kraemer C, et al., Treatment of childhood migraine attacks with oral zolmitriptan and ibuprofen. Neurology. 2006; 67: 497-499.
42. Lewis DW, Winner P, Hershey AD, Wasiewski WW., On behalf of the adolescent migraine steering committee. Efficacy of zolmitriptan nasal spray in adolescent migraine. Pediatrics. 2007; 120: 390-396.
43. Winner P, Woodruff B, Liss CS, Lillieborg S, Raines S., Efficacy and safety of zolmitriptan nasal spray for the treatment of acute migraine in adolescents. (2015), Late Breaking Abstracts: 57th Annual Scientific Meeting of the American Headache Society. Headache J Head Face Pain. doi: 10.1111/head.12693.
44. Ueberall MA, Wenzel D., Intranasal sumatriptan for the acute treatment of migraine in children. Neurology. 1999; 57: 1507-1510.
45. Winner P, Rothner AD, Saper J, et al., A randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in the treatment of acute migraine in adolescents. Pediatrics. 2000; 106: 989-997.
46. Ahonen K, Hämäläinen ML, Rantala H, Hoppu K., Nasal sumatriptan is effective in treatment of migraine attacks in children A randomized trial. Neurology. 2004; 62: 883-887.
47. MacDonald JT., Treatment of juvenile migraine with subcutaneous sumatriptan. Headache J Head Face Pain. 1994; 34: 581-582.
48. Linder SL., Subcutaneous sumatriptan in the clinical setting: the first 50 consecutive patients with acute migraine in a pediatric neurology office practice. Headache J Head Face Pain. 1996; 36: 419-422.
49. Hämäläinen ML, Hoppu K, Santavuori P., Sumatriptan for migraine attacks in children: A randomized placebo-controlled study Do children with migraine respond to oral sumatriptan differently from adults? Neurology. 1997; 48: 1100-1103.
50. McDonald SA, Hershey AD, Pearlman E, et al., Long-term evaluation of sumatriptan and naproxen sodium for the acute treatment of migraine in adolescents. Headache J Head Face Pain. 2011; 51: 1374-1387.
51. Derosier FJ, Lewis D, Hershey AD, et al., Randomized trial of sumatriptan and naproxen sodium combination in adolescent migraine. Pediatrics. 2012; 129: e1411-e1420.
52. Silberstein SD, Shashidhar HK., Dihydroergotamine: A review of formulation approaches for acute treatment of migraine. CNS Drugs. 2013; 27: 385-394.
53. Saper JR, Silberstein S., Pharmacology of dihydroergotamine and evidence for efficacy and safety in migraine. Headache J Head Face Pain. 2006; 46: S171-S181.
54. Nagy AJ, Gandhi S, Bhola R, Goadsby PJ., Intravenous dihydroergotamine for inpatient management of refractory primary headaches. Neurology. 2011; 77: 1827-1832.
55. Raskin NH., Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology, 1986; 36: 995-997.
56. Linder SL., Treatment of childhood headache with dihydroergotamine mesylate. Headache J Head Face Pain. 1994; 34: 578-580.
57. Kabbouche MA, Powers SW, Segers A, et al., Inpatient treatment of status migraine with dihydroergotamine in children and adolescents. Headache J Head Face Pain. 2009; 49: 106-109.
58. Hämäläinen ML, Hoppu K, Santavuori PR., Oral dihydro-ergotamine for therapy-resistant migraine attacks in children. Pediatr Neurol. 1997; 16: 114-117.
59. Bigal ME, Lipton RB, Winner P, Reed ML, Diamond S, Stewart WF., Migraine in adolescents. Association with socioeconomic status and family history. Neurology. 2007; 69: 16-25.